Onconova Therapeutics, Inc. (ONTX) announced Tuesday that it has acquired Trawsfynydd Therapeutics, Inc., a privately-held biotechnology company developing antivirals for influenza, COVID and other infectious diseases, in an all-stock transaction.The combined company has been renamed Traws Pharma, Inc., and will trade on NASDAQ under the new ticker symbol 'TRAW', commencing prior to the opening of trading Wednesday, April 3.In connection with the merger, the stockholders of Traswfynydd received an aggregate of 3.55 million shares of common stock and 10,359.0916 shares of newly issued Series C non-voting convertible preferred stock.Traws will be led by incoming Chief Executive Officer, Werner Cautreels.In connection with the Merger, Traws announced that it will raise $14 million in a committed private placement financing by OrbiMed and Torrey Pines, expected to close on April 3.

Onconova Therapeutics，Inc.（ONTX）周二宣布，已通过全股票交易收购Trawsfynyd Therapeutics，Inc.，这是一家私营生物技术公司，开发针对流感、新型冠状病毒和其他传染病的抗病毒药物。合并后的公司更名为Traws Pharma，Inc.，将于4月3日（星期三）开盘前在纳斯达克以新的股票代码“TRAW”进行交易。就合并而言，Traswfynydd的股东共收到355万股普通股和10359.0916股新发行的C系列无投票权可转换优先股。Traws将由新任首席执行官沃纳·考特雷尔斯（WernerCautreels）领导。在合并方面，Traws宣布将通过OrbiMed和TorreyPines承诺的私募融资筹集1400万美元，预计将于4月3日结束。

Upon closing of the private placement, Traws expects to have in excess of $28 million of cash and cash equivalents from the proceeds of the private placement and cash from both companies..

私募结束后，Traws预计将从私募收益和两家公司的现金中获得超过2800万美元的现金和现金等价物。

These proceeds will be used to advance the Traws' programs through multiple clinical data catalysts and complete the dose ranging study for narazaciclib.Cautreels, incoming Chief Executive Officer of the combined company, said, 'I am pleased to announce the combination of Onconova and Trawsfynydd at this important time, as Trawsfynydd readies to initiate Phase 2 studies in H2 2024 for its lead antiviral programs for influenza and COVID19, supported by advisors with unparalleled expertise in viral disease, and Onconova is preparing to finalize the recommended Phase 2 dose (RP2D) for narazaciclib.'For More Such Health News, visit rttnews.com For comments and feedback contact: editorial@rttnews.comBusiness News.

这些收益将用于通过多种临床数据催化剂推进Traws的计划，并完成纳拉唑西利的剂量范围研究。合并后的公司新任首席执行官考特雷尔斯（Cautreels）表示，“我很高兴在这个重要时刻宣布Onconova和Trawsfynyd的合并，Trawsfynyd准备在2024年下半年启动针对流感和新型冠状病毒19的主要抗病毒项目的第二阶段研究，并得到在病毒性疾病方面具有无与伦比专业知识的顾问的支持，Onconova正在准备最终确定纳拉唑西林的推荐第二阶段剂量（RP2D）。”有关更多此类健康新闻，请访问rttnews.com以获取评论和反馈联系：editorial@rttnews.comBusiness新闻。